Evaluation of Comfort for Two Marketed Daily Disposable Contact Lenses

Johnson & Johnson (J&J)

Status

Completed

Conditions

Visual Acuity

Treatments

Device: Precision 1

Device: ACUVUE Oasys 1-Day

Study type

Interventional

Funder types

Industry

Identifiers

NCT04968925

CR-6456

Details and patient eligibility

About

This study is a 2-phase adaptive approach utilizing a 2×2 crossover design. The study lenses will be worn in a bilateral fashion for a period of approximately 1-week each.

Enrollment

302 patients

Sex

All

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Potential subjects must satisfy all of the following criteria to be enrolled in the study:

Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
Appear able and willing to adhere to the instructions set forth in this clinical protocol.
Be between 18 and 40 (inclusive) years of age at the time of screening.
By self-report, habitually wear soft spherical contact lenses in both eyes in a daily disposable wear modality. Habitual wear is defined as a minimum of 8 hours of wear per day, for a minimum of 4 days per week during the past 4 weeks.
By self-report, typically uses computer screens and other digital devices (phones, tablets) at least 30 hours per week.
The vertex-corrected best spherical distance refraction (rounded to nearest 0.25 D) must be between -1.00 and -4.00 DS (inclusive) in each eye.
The magnitude of the cylinder component of the subject's distance refraction must be 1.00 DC or less.
The subject must have best corrected visual acuity of 20/25 or better in each eye.

Exclusion criteria

Potential subjects who meet any of the following criteria will be excluded from participating in the study:

Be currently pregnant or breastfeeding
By self-report, have any ocular or systemic disease, allergies, infection, or use of medication that might contraindicate or interfere with contact lens wear, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g. rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures. See Section 9.1 for additional details regarding excluded systemic medications.
Have had any previous ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, cataract, etc.).
Habitually wear monovision, multifocal, toric, or extended wear contact lens correction
Have participated in any contact lens or lens care product clinical trial within 14 days prior to study enrollment
Be an employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician)
Have a history of amblyopia or strabismus.
Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (eg, SynergEyes) within the past 6 months.
Have clinically significant (Grade 3 or higher on the FDA grading scale) slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection) or other corneal or ocular disease or abnormalities that contraindicate contact lens wear or may otherwise compromise study endpoints (including entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis).
Have any ocular infection.